Arbidol

For the prevention and control of respiratory virus infections, broad-spectrum antiviral drugs have always been one of the core options for clinical response. Arbidol is an antiviral drug belonging to the hemagglutinin inhibitor class. It blocks the viral replication cycle by inhibiting the fusion of the viral envelope with the host cell membrane. Meanwhile, it can induce the production of endogenous interferon and regulate immune function, and has inhibitory activity against a variety of respiratory pathogens such as influenza A and B viruses and respiratory syncytial virus. Clinically, it is mainly used for the prevention and treatment of influenza in adults and children, and has also been included in relevant diagnosis and treatment protocols for respiratory virus infections, making it an important antiviral reserve drug in the public health prevention and control system.

From the perspective of the global market, the demand for arbidol shows a steady growth trend driven by seasonal influenza epidemics and the demand for prevention and control of respiratory infectious diseases. In 2023, the global market size was approximately USD 320 million, with a compound annual growth rate maintained at around 6.8%. The domestic market is currently dominated by generic drug supplies, with the original research product accounting for less than 10% of the market share. As of 2024, arbidol preparations from 12 enterprises have been approved for marketing, among which 3 products have been included in the national centralized drug procurement. The price of the selected products has dropped by more than 70% compared with the maximum price limit, which has greatly improved clinical accessibility. The upstream API link is mainly supplied by local enterprises, and the registered production capacity can meet the needs of domestic preparation production and partial export.

The original research enterprise of arbidol is Pharmstandard of Russia, and the original trade name is Arbidol. Its core compound patent in Russia expired in 2021, and the relevant preparation patent in China expired in 2023. The main dosage forms of the original research product are tablets and granules, with common specifications of 0.1g per tablet and 0.05g per bag. It has been included in the national drug catalogs of many countries such as Russia and Kazakhstan, and is a first-line drug for clinical influenza treatment in these regions. At present, arbidol APIs from 11 domestic enterprises have obtained A status through CDE registration, which can be used in association with preparation declaration. The corresponding approved preparations cover three dosage forms: tablets, capsules and granules. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for arbidol API. Most products are in stock, and in-stock products ordered before 16:00 will be shipped on the same day. They comply with the regulatory requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can fully cover the needs of the whole process including API quality research, preparation stability investigation, registration and declaration, etc., providing reliable reference standard support for the R&D and production links of relevant enterprises.